Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Seres Therapeutics's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0, down 100.0% from the year before. The highest annual figure on record is $101.54M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $101.54M | +100.7% |
| FY2022 | Dec 31, 2022 | $50.59M | +105.3% |
| FY2021 | Dec 31, 2021 | $24.64M | +0.0% |
| FY2020 | Dec 31, 2020 | $24.64M | -0.0% |
| FY2019 | Dec 31, 2019 | $24.65M | +1790.2% |
| FY2014 | Dec 31, 2014 | $1.30M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $102.49M | +1.7% |
| Q1 FY2024 | Mar 31, 2024 | $102.01M | +99.1% |
| Q4 FY2023 | Dec 31, 2023 | $101.54M | +100.7% |
| Q3 FY2023 | Sep 30, 2023 | $101.14M | +98.9% |
| Q2 FY2023 | Jun 30, 2023 | $100.74M | +99.0% |
| Q1 FY2023 | Mar 31, 2023 | $51.23M | +1.6% |
| Q4 FY2022 | Dec 31, 2022 | $50.59M | +105.3% |
| Q3 FY2022 | Sep 30, 2022 | $50.86M | +215.5% |
| Q2 FY2022 | Jun 30, 2022 | $50.63M | +166.0% |
| Q1 FY2022 | Mar 31, 2022 | $50.44M | +130.6% |
| Q4 FY2021 | Dec 31, 2021 | $24.64M | +0.0% |
| Q3 FY2021 | Sep 30, 2021 | $16.12M | -35.5% |
| Q2 FY2021 | Jun 30, 2021 | $19.04M | -23.4% |
| Q1 FY2021 | Mar 31, 2021 | $21.87M | -11.6% |
| Q4 FY2020 | Dec 31, 2020 | $24.64M | -0.0% |
| Q3 FY2020 | Sep 30, 2020 | $24.98M | – |
| Q2 FY2020 | Jun 30, 2020 | $24.86M | – |
| Q1 FY2020 | Mar 31, 2020 | $24.75M | – |
| Q4 FY2019 | Dec 31, 2019 | $24.65M | – |
See a number that looks wrong?